GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (OTCPK:BVAXF) » Definitions » EV-to-EBITDA

BioVaxys Technology (BioVaxys Technology) EV-to-EBITDA : -3.33 (As of May. 28, 2024)


View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, BioVaxys Technology's enterprise value is $7.88 Mil. BioVaxys Technology's EBITDA for the trailing twelve months (TTM) ended in Jul. 2023 was $-2.36 Mil. Therefore, BioVaxys Technology's EV-to-EBITDA for today is -3.33.

The historical rank and industry rank for BioVaxys Technology's EV-to-EBITDA or its related term are showing as below:

BVAXF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -53.17   Med: 0   Max: 2.08
Current: -3.4

During the past 5 years, the highest EV-to-EBITDA of BioVaxys Technology was 2.08. The lowest was -53.17. And the median was 0.00.

BVAXF's EV-to-EBITDA is ranked worse than
100% of 451 companies
in the Biotechnology industry
Industry Median: 9.51 vs BVAXF: -3.40

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-28), BioVaxys Technology's stock price is $0.06. BioVaxys Technology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jul. 2023 was $-0.088. Therefore, BioVaxys Technology's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


BioVaxys Technology EV-to-EBITDA Historical Data

The historical data trend for BioVaxys Technology's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology EV-to-EBITDA Chart

BioVaxys Technology Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Oct22
EV-to-EBITDA
- -5.87 -26.13 -5.20 -5.43

BioVaxys Technology Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.41 -5.43 -3.17 -1.67 -0.91

Competitive Comparison of BioVaxys Technology's EV-to-EBITDA

For the Biotechnology subindustry, BioVaxys Technology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioVaxys Technology's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVaxys Technology's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BioVaxys Technology's EV-to-EBITDA falls into.



BioVaxys Technology EV-to-EBITDA Calculation

BioVaxys Technology's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=7.877/-2.363
=-3.33

BioVaxys Technology's current Enterprise Value is $7.88 Mil.
BioVaxys Technology's EBITDA for the trailing twelve months (TTM) ended in Jul. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.36 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioVaxys Technology  (OTCPK:BVAXF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

BioVaxys Technology's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.06/-0.088
=At Loss

BioVaxys Technology's share price for today is $0.06.
BioVaxys Technology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jul. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.088.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


BioVaxys Technology EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


BioVaxys Technology (BioVaxys Technology) Business Description

Traded in Other Exchanges
Address
146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4
BioVaxys Technology Corp is a clinical-stage biopharma company. The company develops antiviral and anticancer vaccine platforms to treat SARS-CoV-2 and other viral infections, as well as ovarian cancer and other solid tumor types.